A case report on Severe Acute Respiratory Infection

Shiva Bawane a†, Manjusha Mahakalkar a‡* and Ruchira Ankar a#

a Smt. Radhikabai Meghe Memorial College of Nursing, Sawangi (Meghe), Wardha, Datta Meghe Institute of Medical Sciences (Deemed to be University), Maharashtra, India.

Authors’ contributions
This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information
DOI: 10.9734/JPRI/2021/v33i57B34047

Open Peer Review History:
This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: https://www.sciarticle5.com/review-history/76720

Received 12 September 2021
Accepted 24 November 2021
Published 14 December 2021

ABSTRACT

Introduction: Severe Acute Respiratory Syndrome is a zootoxic viral respiratory illness caused by the severe acute respiratory syndrome corona virus (SARS-CoV or SARS-The syndrome was the cause of the Severe Acute Respiratory Syndrome outbreak in 2002–2004. The virus was traced back to cave-dwelling horseshoe bats via Asian palm civets in late 2017 by Chinese scientists in Xizang Yi Ethnic Township, Yunnan. SARS was a rare illness; there were 8,422 cases at the end of the pandemic in June 2003, with an 11 percent case fatality rate (CFR) (CoV-1), the initial strain of the SARS corona virus species (SARSr-CoV).

Clinical Finding: Swelling of Right. Half of face, Breathlessness.

Diagnostic Evaluation: Blood test: Hb – 9.2gm%, Total RBC count- 3.22 millions/cu.mm, HCT-26.6%, Total WBC count – 6600/cu.mm, Monocytes-02%, granulocytes-85%, lymphocytes-10000 /mcl. HRCT Scan OF Thorax: Multiple ill defined patchy ground glass opacities with consolidation and sepal thickening in bilateral lungs filled s/o infective etiology possibility of atypical viral pneumonia. View of covid positive PCR test; imagine grading corad-6 with CT severity score – 03/25 (Mild).

Therapeutic Intervention: Inj.Amphotericin-B 500mg IV, Inj.Piptaz 4.4gm IV x TDS, Inj.levoflox 500 mg x OD, Inj.Clindamycin 300mg x BD, Inj.pantaprazol 40 mg x OD, Inj.Emset 4mg x TDS, Tab. limcee 500 mg x BD.

Outcome: After Treatment, the patient shows improvement. His swelling over face decrease, and breathlessness decrease.

†Basic BSc. Nursing;
‡Head of Department Gynecology;
#Assistant Professor Medical Surgical Nursing;
*Corresponding author: E-mail: manjum4725@gmail.com;
Conclusion: My patient was admitted in SARI-HDU, AVBRH with complaint of swelling over face Right side, and breathlessness. After getting appropriate treatment his condition was improved.

Keywords: Corona virus; respiratory syndrome; breathlessness.

1. INTRODUCTION

The severe acute respiratory syndrome corona virus (SARS-CoV or SARS-CoV-1) is a zoonotic viral respiratory illness caused by the severe acute respiratory syndrome corona virus (SARS-CoV or SARS-CoV-1), the first known strain of the SARS corona virus species (SARSr-CoV). The first corona virus linked to SARS was found (SARSr-CoV). The syndrome was the cause of the SARS outbreak in 2002–2004. The virus was traced back to cave-dwelling horseshoe bats via Asian palm civets in late 2017 by Chinese scientists in Xizang Yi Ethnic Township, Yunnan [1]. Severe Acute Respiratory Syndrome was a very rare disease; there were 8,422 cases at the end of June 2003, with an 11 percent case fatality rate (CFR) [2]. Since 2004, there have been no confirmed cases of SARS-CoV-1 anywhere on the planet [3]. In December 2019, SARS-CoV 2 (severe acute respiratory syndrome corona virus 2) was found as a new SARS-CoV strain.

SARS-CoV-1 replicates in the same way as other corona viruses [4-10]. The virus’s main human receptors are angiotensin-converting enzyme 2 (ACE2) and hemaglutinin (HE), both identified in 2003. In humans, SARS-CoV-1 appears to have a complex history of recombination with ancestral corona viruses identified in a number of animal species. Recombination requires the presence of at least two SARS-CoV-1 genomes in the same host cell. During genome replication, recombination can occur when the RNA polymerase switches from one template to another.

(SARS-CoV-2) [11] The major route of transmission for SARS-CoV is mucosal membrane contact with respiratory droplets or fomites. Despite the fact that diarrhea is a common symptom of Severe Acute Respiratory Syndrome, the fecal–oral route does not appear to be a primary mode of transmission [12]. The reproduction, R0, of Severe Acute Respiratory Syndrome-basic CoV ranges from 2 to 4 depending on the analysis. Control measures were applied in April 2003, reducing the R to 0.4 [12].

Patient Identification: A male of age 30 year old admitted to SARI-HDU, AVBRH on 19th May 2021 with complaint of swelling over right side of face and Breathlessness. He is 55 kg and Height is 172 cm.

Present Medical History: A male of age 30 year old was brought to AVBRH with a complaint of swelling over Right side of face and Breathlessness admitted to SARI-HDU .After investigation he is diagnose as Severe Acute Respiratory infection.

Past Medical History: My patient was diagnosed as covid-19 before one month ago he takes covid-19 treatment from Mahatma Gandhi Institute Of medical Science; Sewagram except this he not has disease like tuberculosis, Hypertension.

Family History: There are four members in the family. Type of marriage of the patient is non-consanguineous marriage. All other members of the family were not having complaint in their health except for my patient who was being admitted in the hospital.

Past Intervention and Outcomes: patient takes treatment of covid-19 from MGIMS hospital . As problem of swelling and breathlessness increase he shifted to AVBRH for her treatment.

Clinical Finding: Swelling over Right half of face, Breathlessness.

Etiology: SARS symptoms include fever, muscular aches, fatigue, cough, sore throat, and other vague symptoms. The sole symptom that everyone has is a temperature above 38 degrees Celsius (100 degrees Fahrenheit). As a result of SARS, people may experience show Rightness of breath and pneumonia, which can be either direct viral pneumonia or secondary bacterial pneumonia.

1. Pharyngitis (inflammation of the throat) Acute pharyngitis (inflammation of the).
2. The virus that causes the flu is called the par influenza virus.
3. Metapneumovirus in humans.
4. Adenovirus is a type of virus.
5. Rhinovirus is a virus that causes rhinitis.

Physical Examination: There is not much abnormality found in Head- to-toe examination only swelling was present on Right side of patient face. The patient is thin and having dull look. Though it is found that patient have a severe acute Respiratory infection from HRCT thorax.

Diagnostic Assessment: Blood test: Hb – 9.2gm%, Total RBC count- 3.22millions/cu.mm, HCT- 26.6%, Total WBC count – 6600/cu.mm, Monocytes-02%, granulocytes-85%, lymphocytes-10000 /ml. HRCT scan of thorax.

Therapeutic Intervention: Inj. Amphotericin-B 500mg IV, Inj.Piptaz 4.4gm x TDS, Inj.leovlox 500 mg x OD, Inj.Clindamycin 300mg x BD, Inj.pantaprazol 40 mg x OD, Inj.Emset 4mg x TDS, Tab.limcee 500mg x Bd.

2. DISCUSSION

On the 19th May 2021, a 30 year old male from Malegaon was brought to AVBRH SARI-HDU (medicine unit) with following symptoms: swelling over face at RIGHT. Side and breathlessness with the use of HRCT scan of thorax. It is determined that the patient has a Severe acute Respiratory Infection. As soon was taken to the hospital an inquiry was conducted and proper treatment began. Following therapy it is critical to detect the condition at an early stage so that the patient does not develop more complications. It is important to take preventive measure my patient show great improvement after getting the treatment and the treatment was still going on till my last day of care.

The etiological and epidemiological characteristics of severe acute respiratory infection were studied in this study. Severe acute respiratory infection (SARI) causes a massive amount of sickness all over the world. Active monitoring among adult hospitalized Severe Acute Respiratory Failure patients is understudied in China. The objective of this pilot study in Jinshan, Shandong, was to identify common etiologies and characterize the demographic, epidemiological, and clinical features of hospitalized SARI patients aged 16 and up. A single sentinel hospital in Shanghai's Jinshan area was under active monitoring from April 2017 to March 2018. Within 24 hours of admission; nasopharyngeal swabs were collected and tested for a variety of respiratory viruses (including 18 common viruses). There were 397 SARI patients in all, with a median age of 68 years and 194 (48.9%) of them being men. At least one chronic medical problem was present in 278 (70.0%) of the patients. The most frequent symptoms were coughing (99.2%), followed by sputum production (88.4%) percent. A ten-day stay in the hospital was the average. 250 infected patients (63.0%) tested positive for at least one pathogen, with 198 (49.9%) testing positive for just one pathogen and 52 (13.1%) testing positive for several infections. M. pneumonia was found in the majority of cases (23.9 percent, 95/397), followed by adenovirus (AdV) (11.6 percent, 46/397), influenza virus A/H3N2 (Flu A/H3N2) (11.1 percent, 44/397), human rhinovirus (HRhV) (8.1 percent, 32/397), influenza virus B/Yamagata (Flu B/Yamagata) (6.3 percent, 25/397), Human bocavirus (HBoV) (0.3 percent, 1/397), pandemic influenza virus B/Victoria (Flu B/Victoria) (0.5 percent, 2/397), and respiratory syncytial virus (RSV) type B (0.5 percent, 2/397) were all discovered. M. pneumonia, AdV, and Flu A/H3N2 were the most frequent infections detected in hospitalized SARI patients aged 16 and above in Shanghai's Jinshan area the corona virus linked to Severe Acute Respiratory Failure produces a viral respiratory illness known as severe acute respiratory syndrome (SARS). It was identified in late February 2003, during a Chinese outbreak that spread to four other countries. With the help of the Global Outbreak AleRight and Response Network, WHO coordinates the international investigation (GOARN) it collaborated closely with health officials in the afflicted nations to offer epidemiological, clinical, and logistical support right in order to contain the epidemic.

Like the common cold and influenza virus, Severe Acute Respiratory Infection is an airborne virus transmitted by small droplets of saliva. It was the first serious and easily transmissible new sickness to emerge in the twenty-first century, and it had the potential to spread over international air travel routes.

Touching surfaces that have been infected with the virus can also spread Severe Acute Respiratory Infection. The majority of patients of Severe Acute Respiratory Syndrome were previously healthy individuals in their late twenties to fifties. A few teenagers under the age of fifteen have been suspected of having Severe
Acute Respiratory Syndrome. The case fatality rate for probable and suspected SARS infections according to the current WHO case definition is around 3%. Our findings highlight the need of long-term multipathogen monitoring among Severe Acute Respiratory Infection patients at sentinel hospitals, which can provide significant information concerning etiologies, epidemiology, and clinical characteristics of Severe Acute Respiratory Infection.

3. CONCLUSION
A male of age 30 year old from Malegaon was admitted to SARI-HDU, AVBRH on 19th May 2021 with complaint of swelling over face on Right side and Breathlessness with the help of HRCT thorax it is diagnose as Severe Acute Respiratory Infection. As soon as he admitted in hospital investigation were done and appropriate treatment were started and after getting treatment, it is a very important to diagnose in early stage so that the patient will not develop complication from the disease. It important to take preventive measure. My patient shows great improvement after getting the treatment and the treatment was still going on till my last day of care.

DISCLAIMER
The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal effort of the authors.

CONSENT
As per international standard or university standard, patient’s written consent has been collected and preserved by the author(s).

ETHICAL APPROVAL
As per international standard or university standard written ethical approval has been collected and preserved by the author(s).

COMPETING INTERESTS
Authors have declared that no competing interests exist.

REFERENCES


Peer-review history:
The peer review history for this paper can be accessed here:
https://www.sdiarticle5.com/review-history/76720